ACOU 085
Alternative Names: ACOU-085Latest Information Update: 11 Jan 2024
At a glance
- Originator Acousia Therapeutics
- Class Oxazoles; Sensory system agents; Small molecules; Thiazoles
- Mechanism of Action KCNQ potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hearing loss
- No development reported Sensorineural hearing loss
Most Recent Events
- 10 Jan 2024 Phase-II clinical trials in Hearing loss (Prevention) in Germany (unspecified route)
- 09 Oct 2023 Acousia Therapeutics receives clinical trial approval from the German regulatory authorities (BfArM) for phase II of ACOU 085 in Hearing loss
- 28 Sep 2023 No recent reports of development identified for preclinical development in Sensorineural hearing loss in Germany (Otic, Gel)